HighTide Therapeutics (02511) Releases Monthly Return for November 2025

Bulletin Express

Dec 02, 2025

HighTide Therapeutics, Inc. (Stock Code: 02511) published its Monthly Return for Equity Issuer on 2 December 2025, reporting no movements in its authorised or issued share capital for November 2025.

The report shows that the company’s authorised share capital remains at 1,000,000,000 ordinary shares with a par value of USD 0.0001 per share, totaling USD 100,000. The total number of issued shares is unchanged at 571,325,668, with no treasury shares.

The announcement also confirms no new share options, warrants, convertibles, or other related arrangements during the month. The issuer states that relevant requirements and listing rules have been fully complied with.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1124992441"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1124992441\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1124992441?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-02 16:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124992441","market":"hk","top_or_hot":-1,"title":"HighTide Therapeutics (02511) Releases Monthly Return for November 2025","media":"Bulletin Express","content":"<p>HighTide Therapeutics, Inc. (Stock Code: 02511) published its Monthly Return for Equity Issuer on 2 December 2025, reporting no movements in its authorised or issued share capital for November 2025.</p>\n<p>The report shows that the company’s authorised share capital remains at 1,000,000,000 ordinary shares with a par value of USD 0.0001 per share, totaling USD 100,000. The total number of issued shares is unchanged at 571,325,668, with no treasury shares.</p>\n<p>The announcement also confirms no new share options, warrants, convertibles, or other related arrangements during the month. The issuer states that relevant requirements and listing rules have been fully complied with.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HighTide Therapeutics (02511) Releases Monthly Return for November 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHighTide Therapeutics (02511) Releases Monthly Return for November 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-12-02 16:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HighTide Therapeutics, Inc. (Stock Code: 02511) published its Monthly Return for Equity Issuer on 2 December 2025, reporting no movements in its authorised or issued share capital for November 2025.</p>\n<p>The report shows that the company’s authorised share capital remains at 1,000,000,000 ordinary shares with a par value of USD 0.0001 per share, totaling USD 100,000. The total number of issued shares is unchanged at 571,325,668, with no treasury shares.</p>\n<p>The announcement also confirms no new share options, warrants, convertibles, or other related arrangements during the month. The issuer states that relevant requirements and listing rules have been fully complied with.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02511","symbol_name":"君圣泰医药-B","start_time":0,"source_url":"","article_id":"1124992441","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124992441","pubTimestamp":1764665510,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"HighTide Therapeutics, Inc. (Stock Code: 02511) published its Monthly Return for Equity Issuer on 2 December 2025, reporting no movements in its authorised or issued share capital for November 2025....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02511":"君圣泰医药-B"},"translate_title":"海泰治疗(02511)发布2025年11月月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02511":1},"content_text":"HighTide Therapeutics, Inc. (Stock Code: 02511) published its Monthly Return for Equity Issuer on 2 December 2025, reporting no movements in its authorised or issued share capital for November 2025.\nThe report shows that the company’s authorised share capital remains at 1,000,000,000 ordinary shares with a par value of USD 0.0001 per share, totaling USD 100,000. The total number of issued shares is unchanged at 571,325,668, with no treasury shares.\nThe announcement also confirms no new share options, warrants, convertibles, or other related arrangements during the month. The issuer states that relevant requirements and listing rules have been fully complied with.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}